



POSTER PRESENTATION

Open Access

Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development

JCA Broen^{1*†}, P Gourh^{2†}, M C Vonk^{1†}, L Beretta³, F Niederer⁴, B Rueda⁵, L Geurts-van Bon¹, C Brouwer¹, R Hesselstrand⁶, A Herrick⁷, J Worthington⁷, N Hunzelman⁸, C Denton⁹, C Fonseca⁹, G Riemekasten¹⁰, H Kiener¹¹, R Scorza³, C P Simeon¹², V Fonollosa¹², P Carreira¹³, N Ortego-Centeno¹⁴, M A Gonzalez-Gay¹⁵, P Airò¹⁶, MJH Coenen¹⁷, M Mayes², D Kyburz⁴, F C Arnett^{2†}, J Martin^{5†}, TRDJ Radstake^{1†}

From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010

Aim

Pre B-cell colony-enhancing factor (PBEF) is intricately involved in inflammation and fibrosis, functional polymorphisms of PBEF have been previously shown to influence PBEF expression and pulmonary damage. Systemic sclerosis (SSc) is a disease in which inflammation, fibrosis and pulmonary deterioration are prominent hallmarks. Therefore we here investigate the role of the *PBEF* -1001T>G and *PBEF* -1543C>T polymorphisms in the genetic predisposition to systemic sclerosis (SSc) susceptibility and pulmonary involvement.

Patients and methods

We genotyped DNA from 2737 SSc patients and 1913 matched healthy controls, both from 8 different ethnic populations. Genotyping was performed using custom Taqman 5' allelic discrimination assays. In addition, PBEF serum expression levels were measured by ELISA and correlated with genotypes.

Results

In two separate populations and in a meta-analysis, the combined *PBEF* -1543CC -1001TT genotype, hence carrying no minor alleles, was found associated with SSc susceptibility ($P=0.009$ OR 1.20 (95% CI 1.05-

1.37). In addition, these subjects showed an increased decline in forced vital capacity (FVC) over 15 years follow-up ($P=0.02$) (HR 1.64, 95%CI: 1.02-2.64) and a higher PBEF serum concentration ($P<0.01$), compared to carriers of minor alleles. On the other hand, patients with genotype *PBEF* -1001TT were at lower risk for PAH development within 15 years of disease onset compared to the carriers with genotypes *PBEF*-1001GG and *PBEF*-1001TG ($P<0.001$) (HR 3.29, 95% CI: 1.52-7.12).

Conclusions

Our data identify PBEF as a novel candidate gene that influences SSc susceptibility, pulmonary function and the development of PAH.

Author details

¹Dept. of Rheumatology, Radboud University Nijmegen Medical Center, The Netherlands. ²Division of Rheumatology and Clinical Immunogenetics, Dept. of Internal Medicine, University of Texas Health Science Center at Houston (UTHSC-H), Houston, TX, USA. ³Referral Center for Systemic Autoimmune Diseases, University of Milan, Italy. ⁴University Hospital Zurich Div. of Rheumatology Zurich, Switzerland. ⁵Instituto de Parasitología y Biomedicina, CSIC, Granada, Spain. ⁶Dept. of Rheumatology, Lund University Hospital, Lund, Sweden. ⁷Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, UK. ⁸Dept. of Dermatology, University of Cologne, Germany. ⁹Centre for Rheumatology, Royal Free and University College Medical School, London, UK. ¹⁰Dept. of Rheumatology and Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz institute. ¹¹Dept. of Internal Medicine, division of Rheumatology, University of Vienna, Austria. ¹²Servicio de Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain. ¹³Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain. ¹⁴Servicio de Medicina Interna, Hospital Clínico Universitario, Granada, Spain. ¹⁵Servicio de Reumatología, Hospital Marques de Valdecillas, Santander, Spain. ¹⁶Servizio di Reumatologia ed Immunologia

† Contributed equally

¹Dept. of Rheumatology, Radboud University Nijmegen Medical Center, The Netherlands

Full list of author information is available at the end of the article

Clinica, Spedali Civili, Brescia, Italy. ¹⁷Dept. of Human Genetics, Radboud University Nijmegen Medical Center, The Netherlands.

Published: 25 November 2010

doi:10.1186/1479-5876-8-S1-P46

Cite this article as: Broen *et al.*: Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development. *Journal of Translational Medicine* 2010 **8**(Suppl 1):P46.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

